The Venture Codex

Led · Series A · Dec 2020

Resolve Biosciences applies its proprietary Molecular Cartography technology to provide the highest-resolution view of subcellular, single-molecule biology. Its fully automated, highly multiplexed single-molecule FISH workflow delivers three-dimensional spatial context at subcellular resolution while preserving tissue samples. The platform emphasizes sensitivity, specificity, and workflow convenience for basic, translational, and clinical research and has been cited in peer-reviewed publications. The underlying technology is modular and expected to incorporate interrogation of DNA, protein, and metabolomic data layers in the future. Resolve has commercially installed workflows at multiple leading European and North American laboratories and intends to scale operations worldwide. The company secured a $71 million Series B and has now raised more than $100 million to accelerate product development and meet growing demand. Resolve Biosciences offers a Molecular Cartography platform that provides multi-analyte, highly multiplex spatial analysis at subcellular resolution while preserving sample tissue. The platform uses proprietary multiplexed single-molecule detection to deliver deep contextual transcriptomic data and can interrogate hundreds of genes in a single run. Resolve positions the technology for applications in oncology, neuroscience, and infectious disease, emphasizing sensitivity, specificity, and workflow convenience. Future solutions aim to add DNA, protein, and metabolomic data layers to the platform. The technology has been under development since 2016 and is currently available through an oversubscribed early access program. The company is privately held and headquartered in Monheim am Rhein, Germany, and recently completed a financing to accelerate product development and industry adoption.